Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moberg Pharma ABMBGPF 36 EV-to-OCF is -20.25 as of Aug. 09, 2026. GuruFocus rates MBGPF with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Moberg Pharma AB ranks better than 88.07% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Moberg Pharma AB's Enterprise Value is $26.37 Mil.
Moberg Pharma AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.30 Mil. Therefore, Moberg Pharma AB's EV-to-OCF for today is -20.25.
The historical rank and industry rank for Moberg Pharma AB's EV-to-OCF or its related term are showing as below:
MBGPF'
s EV-to-OCF Range Over the Past 10 Years
Min: -94.05 Med: -2.65 Max: 55.02
Current: -20.52
During the past 13 years, the highest EV-to-OCF of Moberg Pharma AB was 55.02. The lowest was -94.05. And the median was -2.65.
MBGPF's EV-to-OCF is ranked better than 88.07% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.06
vs MBGPF: -20.52
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Moberg Pharma AB (OTCPK:MBGPF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Moberg Pharma AB's PE Ratio (TTM) for today is calculated as:
Moberg Pharma AB's share price for today is $1.10.
Moberg Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.059.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Moberg Pharma AB EV-to-OCF Related Terms
Moberg Pharma AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's EV-to-OCF falls into.
Moberg Pharma AB's current Enterprise Value is $26.37 Mil.
Moberg Pharma AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moberg Pharma AB (MBGPF) has a EV-to-OCF of -20.25 as of Aug. 09, 2026. According to the industry distribution chart, Moberg Pharma AB ranks #120 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 11.9%.
Is Moberg Pharma AB's EV-to-OCF too high?
Moberg Pharma AB's current EV-to-OCF is -20.25. Based on the distribution chart, Moberg Pharma AB ranks #120 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #120 out of 1006 companies for EV-to-OCF. This places Moberg Pharma AB in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 11.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.06, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current EV-to-OCF is -20.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (MBGPF) has a current EV-to-OCF of -20.25. The current EV-to-OCF is -20.25. Moberg Pharma AB's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Moberg Pharma AB (MBGPF), the current EV-to-OCF is -20.25 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
36GF Score
Get the complete analysis for MBGPF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBGPF has been successfully added to your 
